Hepatitis C virus spontaneous clearance: Immunology and genetic variance

Viral Immunology

Volumn 25, Issue 4, 2012, Pages 241-248

  Amini, Marzyeh ^a   Poustchi, Hossein ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 28B;

DNA POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; NONHUMAN; REVIEW; VIRAL CLEARANCE;

CYTOKINES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; POLYMORPHISM, GENETIC; VIRAL LOAD;

EID: 84865045268     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0052     Document Type: Review

References (79)

1. Alric L, Fort M, Izopet J, et al.: Study of host- and virusrelated factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens 2000;56:154-158.
2. Alric L, Fort M, Izopet J, et al.: Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997;113:1675-1681.
3. Alter HJ, and Seeff LB: Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.
4. An P, Thio CL, Kirk GD, et al.: Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance. J Infect Dis 2008;198:1159-1165.
5. Arimitsu J, Hirano T, Higa S, et al.: IL-18 gene polymorphisms affect IL-18 production capability by monocytes Biochem Biophys Res Commun 2006;342:1413-416.
6. Barrett S, Goh J, Coughlan B, et al.: The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: Spontaneous viral clearance and chronic HCV infection. Gut 2001;49:423-430.
7. Bream JH, Carrington M, O'Toole S, et al.: Polymorphisms of the human IFNG gene noncoding regions. Immunogenetics 2000;51:50-58.
8. Cacciarelli TV, Martinez OM, Gish RG, et al.: Immunoregulatorycytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alfa. Hepatology 1996;24:6-9.
9. Chang KM, Thimme R, Melpolder JJ, et al.: Differential CD4( + ) and CD8( + ) T-cell responsiveness in hepatitis C virus infection. Hepatology 2001;33:267-276.
10. Chuang TC, Liu JY, Lin CT, et al.: Human manganese superoxide dismutase suppresses HER2/neu-mediated breast cancer malignancy. FEBS Lett 2007;581:4443-4449.
11. Cox AL, Netski DM, Mosbruger T, et al.: Prospective evaluation of community-Acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005;40:951-958.
12. Cramp ME, Carucci P, Underhill J, et al.: Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998;29:207-213.
13. Delpuech O, Buffello-Le Guillou DB, et al.: The hepatitis C virus (HCV) induces a long-term increase in interleukin-10 production by human CD4 + T cells (H9). Eur Cytokine Netw 2001;12:69-77.
14. Eskdale J, McNicholl J, Wordsworth P, et al.: Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet 1998;352:1282-1283.
15. Fainboim L, Chernavsky A, Paladino N, et al.: Cytokines and chronic liver disease. Cytokine Growth Factor Rev 2007; 18:143-157.
16. Frese M, Schwarzle V, Barth K, et al.: Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002;35:694-703.
17. Ge D, Fellay J, Thompson AJ, et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
18. Gerlach JT, Diepolder HM, Zachoval R, et al.: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88.
19. Giedraitis V, He B, Huang WX, et al.: Cloning and mutation analysis of the human IL-18 promoter: A possible role of polymorphisms in expression regulation. J Neuroimmunol 2001;112:146-152.
20. Hamed NA, Raouf HA, Gamal M, and Eissa M: Relationship between HLA-DRB1*0101, DRB1*0301 alleles and interleukin-12 in haemophilic patients and hepatitis C virus positive hepatocellular carcinoma patients. Egypt J Immunol 2003;10:17-26.
21. Harcourt G, Hellier S, Bunce M, et al.: Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat 2001;8:174-179.
22. Harris RA, Sugimoto K, Kaplan DE, et al.: Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology 2008;48:70-79.
23. Hierro L, Alvarez L, Andueza S, et al.: Influence of IL28B gene polymorphisms on sustained response to peginterferon plus ribavirin in children with chronic hepatitis C. J Hepatol 2011;54:S524, abstract 1328.
24. Higashi Y, Kamikawaji N, Suko H, et al.: Analysis of HLA alleles in Japanese patients with cirrhosis due to chronic hepatitis C. J Gastroenterol Hepatol 1996;11:241-246.
25. Hofer H, Watkins-Riedel T, Janata O, et al.: Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003;37:60-64.
26. Hohler T, Kruger A, Gerken G, et al.: Tumor necrosis factor alpha promoter polymorphism at position - 238 is associated with chronic active hepatitis C infection. J Med Virol 1998;54:173-177.
27. Hong X, Yu RB, Sun NX, et al.: Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: A meta-Analysis. World J Gastroenterol 2005;11:7302-7307.
28. Huang Y, Yang H, Borg BB, et al.: A functional SNP of interferon-gamma gene is important for interferon-Alphainduced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA 2007;104:985-990.
29. Hue CP, Renou C, Halfon P, et al.: Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. J Infect Dis 2002;186:106-109.
30. Hwang SJ, Lee SD, Lu RH, et al.: Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. J Med Virol 2001;65:505-509.
31. Kim AY, Kuntzen T, Timm J, et al.: Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 2011;140: 686-696.
32. Kotenko SV, Gallagher G, Baurin VV, et al.: IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77.
33. Ksiaa L, Ayed-Jendoubi S, Sfar I, et al.: Clearance and persistence of hepatitis C virus in a Tunisian population: Association with HLA class I and class II. Viral Immunol 2007; 20:312-319.
34. Lechner F, Wong DK, Dunbar PR, et al.: Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-512.
35. Lio D, Caruso C, Di Stefano R, et al.: IL-10 and TNF-Alpha polymorphisms and the recovery from HCV infection. Hum Immunol 2003;64:674-680.
36. Lopez De Castro JA: HLA-B27: Portraying immunodominant viral epitopes. Eur J Immunol 2005;35:336-340.
37. Mangia A, Gentile R, Cascavilla I, et al.: HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999;30:984-989.
38. Mangia A, Santoro R, Piattelli M, et al.: IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine 2004;25:103-109.
39. Marcello T, Grakoui A, Barba-Spaeth G, et al.: Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006;131:1887-1898.
40. McCarthy JJ, Li JH, Thompson A, et al.: Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010;138:2307-2314.
41. McKiernan SM, Hagan R, Curry M, et al.: Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004;40:108-114.
42. Minton EJ, Smillie D, Neal KR, et al.: Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent epatitis C Virus Study Group. J Infect Dis 1998;178:39-44.
43. Morrow MP, Pankhong P, Laddy DJ, et al.: Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009;113:5868-5877.
44. Neumann-Haefelin C, McKiernan S, Ward S, et al.: Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 2006;43:563-572.
45. Paladino N, Fainboim H, Theiler G, et al.: Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol 2006;80: 9144-9150.
46. Payer B, Reiberger T, Ferenci P, et al.: Prediction of RVR and SVR by IL28B polymorphism combined with IP10 levels in HIV-HCV coinfected patients. J Hepatol 2011;54:S528, abstract 1337.
47. Pravica V, Asderakis A, Perrey C, et al.: In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 1999;26: 1-3.
48. Rao H, Sun D, Jiang D, et al.: IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Hepatol 2011;54:S529, abstract 1339.
49. Rauch A, Kutalik Z, Descombes P, et al.: Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 2010;138:1338-1345, e1331-1337.
50. Rehermann B, and Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-229.
51. Ruiz Estremera A, Munoz-Gamez N, Quiles-Perez R, et al.: Study of genetic variation in IL28B and vertical transmission of hepatitis C virus and spontaneous clearance of childhood HCV infection. J Hepatol 2011;54:S530, abstract 1342.
52. Schvoerer E, Navas MC, Thumann C, et al.: Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy. J Med Virol 2003;70:588-593.
53. Scotto G, Fazio V, D'Alessandro G, et al.: Association between HLA class II antigens and hepatitis C virus infection. J Biol Regul Homeost Agents 2003;17:316-321.
54. Seeff LB, and Hoofnagle JH: Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003;7:261-287.
55. Sheppard P, Kindsvogel W, Xu W, et al.: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-68.
56. Stewart-Jones GB, di Gleria K, Kollnberger S, et al.: Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. Eur J Immunol 2005;35:341-351.
57. Suppiah V, Moldovan M, Ahlenstiel G, et al.: IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet 2009;41:1100-1104.
58. Szabo G, Chang S, and Dolganiuc A: Altered innate immunity in chronic hepatitis C infection: Cause or effect? Hepatology 2007;46:1279-1290.
59. Tanaka Y, Nishida N, Sugiyama M, et al.: Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109.
60. Thimme R, Bukh J, Spangenberg HC, et al.: Viral and immunological eterminants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002;99: 15661-15668.
61. Thimme R, Lohmann V, and Weber F: A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 2006;69:129-141.
62. Thimme R, Oldach D, Chang K, et al.: Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406.
63. Thio CL: Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis 2008;12:713-726, xi.
64. Thio CL, Gao X, Goedert JJ, et al.: HLA-C.w*04 and hepatitis C virus persistence. J Virol 2002;76:4792-4797.
65. Thio CL, Thomas DL, Goedert JJ, et al.: Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001;184:16-21.
66. Thomas DL, Astemborski J, Rai RM, et al.: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.
67. Thomas DL, Thio CL, Martin MP, et al.: Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
68. Thursz M, Yallop R, Goldin R, et al.: Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999;354:2119-2124.
69. Tillmann HL, Thompson AJ, Patel K, et al.: A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010;139: 1586-1592, e1581.
70. Turner DM, Williams DM, Sankaran D, et al.: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
71. Vidigal PG, Germer JJ, and Zein NN: Polymorphisms in the interleukin-10, tumor necrosis factor-Alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002;36:271-277.
72. Villano SA, Vlahov D, Nelson KE, et al.: Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914.
73. Wang JH, Zheng X, Ke X, et al.: Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J 2009;6:46.
74. Wiese M, Berr F, Lafrenz M, et al.: Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 2000; 32:91-96.
75. Woollard DJ, Grakoui A, Shoukry NH, et al.: Characterization of HCV-specific Patr class II restricted CD4 + T cell responses in an acutely infected chimpanzee. Hepatology 2003;38:1297-1306.
76. Yee LJ, Tang J, Herrera J, et al.: Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000;1:386-390.
77. Yenigun A, and Durupinar B: Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J Virol 2002;76:1787-1789.
78. Yoon SK, Han JY, Pyo CW, et al.: Association between human leukocytes antigen alleles and chronic hepatitis C virus infection in the Korean population. Liver Int 2005;25:1122-1127.
79. Zhou Y, Yamaguchi E, Hizawa N, et al.: Roles of functional polymorphisms in the interleukin-18 gene promoter in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22: 105-113.